Role of ABCG2/BCRP in biology and medicine

Annual Review of Pharmacology and Toxicology

Volumn 46, Issue , 2006, Pages 381-410

  Krishnamurthy, P ^a   Schuetz, J D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ABC transporter; Cancer; Drug resistance; Heme; Hypoxia; Stem cells

Indexed keywords

4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BCP 1350; BISANTRENE; BREAST CANCER RESISTANCE PROTEIN; CARCINOGEN; CYTOTOXIN; DAUNORUBICIN; DIFLOMOTECAN; DOXORUBICIN; EXATECAN; FLAVONOID; FLAVOPIRIDOL; GEFITINIB; GF 120998; GLYCOPROTEIN P; HAMMERHEAD RIBOZYME; HEME; HOE 33342; IMATINIB; IRINOTECAN; J 107088; K 0143; LAMIVUDINE; LURTOTECAN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (3 MORPHOLINOPROPOXY) 6 QUINAZOLINYL]ACRYLAMIDE; NATURAL PRODUCT; NUCLEOSIDE ANALOG; PANTOPRAZOLE; PORPHYRIN; PRAZOSIN; PROTOPORPHYRIN; QUINAZOLINE; RESERPINE; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG;

ABCG2 GENE; ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; CANCER; CELL PROTECTION; CELLULAR IMMUNITY; DIMERIZATION; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; GENE; GENE CONTROL; GENE DISRUPTION; HOST RESISTANCE; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; STEM CELL; STRUCTURE ANALYSIS; TISSUE DISTRIBUTION; UPREGULATION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHROMOSOMES; CLONING, MOLECULAR; DRUG THERAPY; GENE EXPRESSION REGULATION; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; STEM CELLS;

EID: 33144479357     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.46.120604.141238     Document Type: Review

References (179)

1. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152-62
2. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, et al. 1986. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-89
3. Gros P, Croop J, Housman D. 1986. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47:371-80
4. Higgins CF, Gottesman MM. 1992. Is the multidrug transporter a flippase? Trends Biochem. Sci. 17:18-21
5. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. 1990. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38:1277-87
6. Konen PL, Currier SJ, Rutherford AV, Gottesman MM, Pastan I, Willingham MC. 1989. The multidrug transporter: rapid modulation of efflux activity monitored in single cells by the morphologic effects of vinblastine and daunomycin. J. Histochem. Cytochem. 37:1141-45
7. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, et al. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502
8. Schinkel AH. 1997. The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol. 8:161-70
9. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:2517-24
10. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, et al. 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-54
11. Dean M, Rzhetsky A, Allikmets R. 2001. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11:1156-66
12. Loo TW, Clarke DM. 1994. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 33:14049-57
13. Hafkemeyer P, Dey S, Ambudkar SV, Hrycyna CA, Pastan I, Gottesman MM. 1998. Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein. Biochemistry 37:16400-9
14. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB. 2003. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 17:2085-87
15. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 95:15665-70
16. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. 1998. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58:5337-39
17. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, et al. 1999. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59:8-13
18. Croop JM, Tiller GE, Fletcher JA, Lux ML, Raab E, et al. 1997. Isolation and characterization of a mammalian homolog of the Drosophila white gene. Gene 185:77-85
19. Ewart GD, Howells AJ. 1998. ABC transporters involved in transport of eye pigment precursors in Drosophila melanogaster. Methods Enzymol. 292:213-24
20. Sullivan DT, Bell LA, Paton DR, Sullivan MC. 1980. Genetic and functional analysis of tryptophan transport in Malpighian tubules of Drosophila. Biochem. Genet. 18:1109-30
21. Sullivan DT, Sullivan MC. 1975. Transport defects as the physiological basis for eye color mutants of Drosophila melanogaster. Biochem. Genet. 13:603-13
22. Sullivan DT, Bell LA, Paton DR, Sullivan MC. 1979. Purine transport by Malpighian tubules of pteridine-deficient eye color mutants of Drosophila melanogaster. Biochem. Genet. 17:565-73
23. Pepling M, Mount SM. 1990. Sequence of a cDNA from the Drosophila melanogaster white gene. Nucleic Acids Res. 18:1633
24. Dreesen TD, Johnson DH, Henikoff S. 1988. The brown protein of Drosophila melanogaster is similar to the white protein and to components of active transport complexes. Mol. Cell. Biol. 8:5206-15
25. Tearle RG, Belote JM, McKeown M, Baker BS, Howells AJ. 1989. Cloning and characterization of the scarlet gene of Drosophila melanogaster. Genetics 122:595-96
26. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. 1999. The mouse Bcrp1/ Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 59:4237-41
27. Ueda T, Brenner S, Malech HL, Langemeijer SM, Perl S, et al. 2005. Cloning and functional analysis of the rhesus macaque ABCG2 gene. Forced expression confers an SP phenotype among hematopoietic stem cell progeny in vivo. J. Biol. Chem. 280:991-98
28. Eisenblatter T, Huwel S, Galla HJ. 2003. Characterisation of the brain multidrug resistance protein (BMDP/AB CG2/BCRP) expressed at the blood-brain barrier. Brain Res. 971:221-31
29. Knutsen T, Rao VK, Ried T, Mickley L, Schneider E, et al. 2000. Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Genes Chromosomes Cancer 27:110-16
30. Doyle LA, Ross DD. 2003. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-58
31. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD. 2001. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim. Biophys. Acta 1520:234-41
32. Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. 2004. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res. 64:1247-51
33. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, et al. 2004. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. 279:24218-25
34. Wang N, Lan D, Chen W, Matsuura F, Tall AR. 2004. ATP-binding cassette transporters Gl and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. USA 101:9774-79
35. Kennedy MA, Venkateswaran A, Tarr PT, Xenarios I, Kudoh J, et al. 2001. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J. Biol. Chem. 276:39438-47
36. Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, et al. 2000. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc. Natl. Acad. Sci. USA 97:817-22
37. Handschin C, Meyer UA. 2005. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch. Biochem. Biophys. 433:387-96
38. Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, et al. 2004. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 279:22250-57
39. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, et al. 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61:3458-64
40. Wang GL, Jiang BH, Rue EA, Semenza GL. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92:5510-14
41. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3:721-32
42. Tanaka Y, Slitt AL, Leazer TM, Maher JM, Klaassen CD. 2005. Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem. Biophys. Res. Commun. 326:181-87
43. Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH. 2005. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol. Pharmacol. 67:1765-71
44. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. 2005. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol. Pharmacol. 67:1758-64
45. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, et al. 2003. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19-28
46. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, et al. 2005. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11:127-29
47. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, et al. 1999. Overexpression of the BCRP/ MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 59:4559-63
48. Imai Y, Ishikawa E, Asada S, Sugimoto Y. 2005. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res. 65:596-604
49. Campbell CH, Bulayeva N, Brown DB, Gametchu B, Watson CS. 2002. Regulation of the membrane estrogen receptor-alpha: role of cell density, serum, cell passage number, and estradiol. FASEB J. 16:1917-27
50. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. 1986. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. USA 83:2496-500
51. Dumesic DA, Renk M, Kamel F. 1989. Estrogenic effects of phenol red on rat pituitary cell responsiveness to gonadotropin-releasing hormone. Life Sci. 44:397-406
52. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, et al. 2001. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7:1028-34
53. Scharenberg CW, Harkey MA, Torok-Storb B. 2002. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507-12
54. Jonker JW, Buitelaar M, Wagenaar E, van der Valk MA, Scheffer GL, et al. 2002. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. USA 99:15649-54
55. Kager L, Cheok M, Yang W, Zaza G, Cheng Q, et al. 2005. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexatepharmacodynamics. J. Clin. Invest. 115:110-17
56. Pastinen T, Sladek R, Gurd S, Sammak A, Ge B, et al. 2004. A survey of genetic and epigenetic variation affecting human gene expression. Physiol. Genomlcs 16:184-93
57. Hirota T, Ieiri I, Takane H, Maegawa S, Hosokawa M, et al. 2004. Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Hum. Mol. Genet. 13:2959-69
58. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, et al. 2005. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. 33:94-101
59. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. 2003. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem. 278:22644-49
60. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. 2004. Expression, up-regulation, and transport activity of the multidrug-resistance protein ABCG2 at the mouse blood-brain barrier. Cancer Res. 64:3296-3301
61. Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y. 2005. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J. Pharmacol Exp. Ther. 312:44-52
62. Cooray HC, Blackmore CG, Maskell L, Barrand MA. 2002. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13:2059-63
63. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. 1996. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183:1797-806
64. Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, et al. 1997. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat. Med. 3:1337-45
65. Bunting KD, Galipeau J, Topham D, Benaim E, Sorrentino BP. 1998. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood 92:2269-79
66. Uchida N, Leung FY, Eaves CJ. 2002. Liver and marrow of adult mdr-1a/1b (-/-) mice show normal generation, function, and multi-tissue trafficking of primitive hematopoietic cells. Exp. Hematol. 30:862-69
67. Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A. 2004. ABCG2-a transporter for all seasons. FEBS Lett. 567:116-20
68. Ujhelly O, Ozvegy C, Varady G, Cervenak J, Homolya L, et al. 2003. Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells. Hum. Gene Ther. 14:403-12
69. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP. 2002. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc. Natl. Acad. Sci. USA 99:12339-44
70. Panwala CM, Jones JC, Viney JL. 1998. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 161:5733-44
71. Wadkins RM, Hyatt JL, Yoon KJ, Morton CL, Lee RE, et al. 2004. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol. Pharmacol. 65:1336-43
72. Wierdl M, Wall A, Morton CL, Sampath J, Danks MK, et al. 2003. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. Mol. Pharmacol. 64:279-88
73. Scheffer GL, Maliepaard M, Pijnenborg AC, van Gastelen MA, de Jong MC, et al. 2000. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res. 60:2589-93
74. Xia CQ, Liu N, Yang D, Miwa G, Gan LS. 2005. Expression, localization, and functional characteristics of breast cancer resistance protein in caco-2 cells. Drug Metab. Dispos. 33:637-43
75. Breuzard G, Angiboust JF, Jeannesson P, Manfait M, Millot JM. 2004. Surface-enhanced Raman scattering reveals adsorption of mitoxantrone on plasma membrane of living cells. Biochem. Biophys. Res. Commun. 320:615-21
76. Hogue DL, Liu L, Ling V. 1999. Identification and characterization of a mammalian mitochondrial ATP-binding cassette membrane protein. J. Mol. Biol. 285:379-89
77. Csere P, Lill R, Kispal G. 1998. Identification of a human mitochondrial ABC transporter, the functional orthologue of yeast Atm1p. FEBS Lett. 441:266-70
78. Kleijmeer MJ, Kelly A, Geuze HJ, Slot JW, Townsend A, Trowsdale J. 1992. Location of MHC-encoded transporters in the endoplasmic reticulum and cis-Golgi. Nature 357:342-44
79. Mosser J, Lutz Y, Stoeckel ME, SardeCO, Kretz C, et al. 1994. The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum. Mol. Genet. 3:265-71
80. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH. 2003. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 63:1339-44
81. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, et al. 2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92:1651-56
82. Mohrmann K, van Eijndhoven MA, Schinkel AH, Schellens JH. 2005. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother. Pharmacol. 56:344-50
83. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, et al. 2001. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun. 285:111-17
84. Diop NK, Hrycyna CA. 2005. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry 44:5420-29
85. Gribar JJ, Ramachandra M, Hrycyna CA, Dey S, Ambudkar SV. 2000. Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J. Membr. Biol. 173:203-14
86. Schinkel AH, Kemp S, Dolle M, Rudenko G, Wagenaar E. 1993. N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J. Biol. Chem. 268:7474-81
87. Graf GA, Yu L, Li WP, Gerard R, Tuma PL, et al. 2003. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J. Biol. Chem. 278:48275-82
88. Ozvegy C, Varadi A, Sarkadi B. 2002. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J. Biol. Chem. 277:47980-90
89. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, Van Veen HW. 2003. Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J. Biol. Chem. 278:20645-51
90. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, et al. 2002. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer 91:626-30
91. Litman T, Jensen U, Hansen A, Covitz KM, Zhan ZR, et al. 2002. Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2. Biochim. Biophys. Acta-Biomembr. 1565:6-16
92. Poelarends GJ, Konings WN. 2002. The transmembrane domains of the ABC multidrug transporter LmrA form a cytoplasmic exposed, aqueous chamber within the membrane. J. Biol. Chem. 277:42891-98
93. Polgar O, Robey RW, Morisaki K, Dean M, Michejda C, et al. 2004. Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry 43:9448-56
94. Chloupkova M, Reaves SK, LeBard LM, Koeller DM. 2004. The mitochondrial ABC transporter Atm1p functions as a homodimer. FEBS Lett. 569:65-69
95. Xu J, Liu Y, Yang Y, Bates S, Zhang JT. 2004. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J. Biol Chem. 279:19781-89
96. Croce AC, Bottiroli G, Supino R, Favini E, Zuco V, Zunino F. 2004. Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem. Pharmacol 67:1035-45
97. Diestra JE, Condom E, Del Muro XG, Scheffer GL, Perez J, et al. 2003. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. J. Urol. 170:1383-87
98. Mizuarai S, Aozasa N, Kotani H. 2004. Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int. J. Cancer 109:238-46
99. Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, et al. 2004. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol. Cell. Biol. 24:8778-89
100. Misra S, Ujhazy P, Gatmaitan Z, Varticovski L, Arias M. 1998. The role of phosphoinositide 3-kinase in taurocholate-induced trafficking of ATP-dependent canalicular transporters in rat liver. J. Biol. Chem. 273:26638-44
101. Takada T, Suzuki H, Gotoh Y, Sugiyama Y. 2005. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab. Dispos. 33:905-9
102. Mogi M, Yang J, Lambert JF, Colvin GA, Shiojima I, et al. 2003. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J. Biol. Chem. 278:39068-75
103. Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG. 2004. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression-a role for BCRP in cellular folate homeostasis. J. Biol Chem. 279:25527-34
104. Misra S, Ujhazy P, Varticovski L, Arias IM. 1999. Phosphoinositide 3-kinase lipid products regulate ATP-dependent transport by sister of P-glycoprotein and multidrug resistance associated protein 2 in bile canalicular membrane vesicles. Proc. Natl. Acad. Sci. USA 96:5814-19
105. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, et al. 2002. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224-32
106. Ross DD, Karp J, Yang W, Gao Y, Abruzzo LV, Doyle LA. 1998. Expression of breast cancer resistance protein (BCRP) in blast cells from patients with acute myeloid leukemia (AML). Blood 92:386A
107. Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG. 2001. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br. J. Haematol. 115:257-62
108. Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper R, Taylor C. 2001. BCRP expression and drug sensitivity in fresh blast cells from patients with AML. Leukemia 15:489
109. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A. 2002. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16:1443-47
110. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, Meijerink JP, Vossebeld PJ, et al. 2002. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 16:833-39
111. Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, et al. 2003. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin. Cancer Res. 9:3320-28
112. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, et al. 2004. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin. Cancer Res. 10:7896-7902
113. Uggla B, Stahl E, Wagsater D, Paul C, Karlsson MG, et al. 2005. BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leukemia Res. 29:141-46
114. Van der Kolk DM, Vellenga E, Scheffer GL, Muller M, Bates SE, et al. 2002. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99:3763-70
115. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, et al. 2001. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98:1166-73
116. Diestra JE, Scheffer GL, Catala I, Maleipaad M, Schellens JHM, et al. 2002. Frequent expression of the multi-drug resistance-associated protein BCRP/ MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J. Pathol. 198:213-19
117. Dean M, Fojo T, Bates S. 2005. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5:275-84
118. Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, et al. 2004. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int. J. Cancer 109:848-54
119. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, et al. 2004. A distinct side populationof cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 101:14228-33
120. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, et al. 2004. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin. Cancer Res. 10:1691-97
121. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, et al. 2003. The breast cancer resistance protein (Bcrpl/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 63:6447-52
122. Keppler D, Konig J. 2000. Hepatic secretion of conjugated drugs and endogenous substances. Semin. Liver Dis. 20:265-72
123. Gerk PM, Oo CY, Paxton EW, Moscow JA, McNamara PJ. 2001. Interactions between cimetidine, nitrofurantoin, and probenecid active transport into rat milk. J. Pharmacol. Exp. Ther. 296:175-80
124. Katritzky AR, Dobchev DA, Hur E, Fara DC, Karelson M. 2005. QSAR treatment of drugs transfer into human breast milk. Bioorg. Med. Chem. 13:1623-32
125. Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, et al. 1995. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA 92:7690-94
126. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. 2003. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol. Pharmacol. 64:610-18
127. Rajendra R, Gounder MK, Saleem A, Schellens JHM, Ross DD, et al. 2003. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxiciry of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res. 63:3228-33
128. Bates SE, Medina-Perez WY, Kohlhagen G, Antony S, Nadjem T, et al. 2004. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins. J. Pharmacol. Exp. Ther. 310:836-42
129. Yoshikawa M, Ikegami Y, Hayasaka S, Ishi K, Ito A, et al. 2004. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int. J. Cancer 110:921-27
130. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, et al. 2004. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 64:1242-46
131. Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. 2003. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. 278:23529-37
132. Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, et al. 2003. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J. Biol. Chem. 278:23538-44
133. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, et al. 2004. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 64:7491-99
134. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, et al. 2005. Gefitinib ("Iressa," ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res. 65:1541-46
135. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, et al. 2004. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 64:2333-37
136. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, et al. 2004. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 65:1485-95
137. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, et al. 2001. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98:3212-20
138. Ejendal KF, Hrycyna CA. 2005. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol. Pharmacol. 67:902-11
139. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, et al. 2001. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 61:739-48
140. Beaudet L, Urbatsch IL, Gros P. 1998. Mutations in the nucleotide-binding sites of P-glycoprotein that affect substrate specificity modulate substrate-induced adenosine triphosphatase activity. Biochemistry 37:9073-82
141. Taguchi Y, Kino K, Morishima M, Komano T, Kane SE, Ueda K. 1997. Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein. Biochemistry 36:8883-89
142. Zhang DW, Cole SP, Deeley RG. 2001. Identification of a nonconserved amino acid residue in multidrug resistance protein 1 important for determining substrate specificity: evidence for functional interaction between transmembrane helices 14 and 17. J. Biol. Chem. 276:34966-74
143. Haimeur A, Conseil G, Deeley RG, Cole SP. 2004. Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). Mol. Pharmacol. 65:1375-85
144. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, et al. 2001. Acquired mutations in the MXR/ BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61:6635-39
145. Allen JD, Jackson SC, Schinkel AH. 2002. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res. 62:2294-99
146. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. 2002. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 62:5035-40
147. Volk EL, Schneider E. 2003. Wild-type breast cancer resistance protein (BCRP/ ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 63:5538-43
148. Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, et al. 2003. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem. J. 373:767-74
149. Janvilisri T, Shahi S, Venter H, Balakrishnan L, Van Veen HW. 2005. Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem. J. 385:419-26
150. Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y. 2003. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. Int. J. Cancer 107:757-63
151. Itoda M, Saito Y, Shirao K, Minami H, Ohtsu A, et al. 2003. Eight novel single nucleotide polymorphisms in ABCG2/ BCRP in Japanese cancer patients administered irinotacan. Drug Metab. Pharmacokinet. 18:212-17
152. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, et al. 2004. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. 21:1895-903
153. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, et al. 2004. Diflomotecan pharmacokinetics in relation to ABCG2 421C > A genotype. Clin. Pharmacol. Ther. 76:38-44
154. Backstrom G, Taipalensuu J, Melhus H, Brandstrom H, Svensson AC, et al. 2003. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur. J. Pharm. Sci. 18:359-64
155. Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, et al. 2005. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br. J. Clin. Pharmacol. 59:415-24
156. Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, et al. 2001. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res. 7:935-41
157. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, et al. 1999. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 59:5938-46
158. Cooray HC, Janvilisri T, Van Veen HW, Hladky SB, Barrand MA. 2004. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun. 317:269-75
159. Yoshikawa M, Ikegami Y, Sano K, Yoshida H, Mitomo H, et al. 2004. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J. Exp. Ther. Oncol. 4:25-35
160. Zhang S, Yang X, Morris ME. 2004. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm. Res. 21:1263-73
161. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, et al. 2000. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 113(Pt. 11):2011-21
162. Rabindran SK, He H, Singh M, Brown E, Collins KI, et al. 1998. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res. 58:5850-58
163. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, et al. 2005. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther. 312:144-52
164. Komatani H, Kotani H, Kara Y, Nakagawa R, Matsumoto M, et al. 2001. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res. 61:2827-32
165. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH. 2003. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 63:1339-44
166. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, et al. 2003. Breast cancer resistance protein (BCRP/ ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol. Pharmacol. 63:65-72
167. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, et al. 2001. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/ BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res. 7:145-52
168. Robey RW, Honjo Y, van de LA, Miyake K, Regis JT, et al. 2001. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim. Biophys. Acta 1512:171-82
169. Wang X, Nitanda T, Shi M, Okamoto M, Furukawa T, et al. 2004. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem. Pharmacol. 68:1363-70
170. Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, et al. 2004. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. Drug Metab. Dispos. 32:722-26
171. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, et al. 2004. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 64:5804-11
172. Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, et al. 2000. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res. 60:3514-21
173. Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP. 2002. Low levels of ABCG2 expression in adult AML blast samples. Blood 100:4594-601
174. Allen JD, van Loevezijn A, Lakhai JM, van d V, van Tellingen O, et al. 2002. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of furnitremorgin C. Mol. Cancer Ther. 1:417-25
175. Kowalski P, Wiehert A, Holm PS, Dietel M, Lage H. 2001. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther. 8:185-92
176. Kowalski P, Stein U, Scheffer GL, Lage H. 2002. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther. 9:579-86
177. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y. 2004. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol. Cancer Ther. 3:1119-25
178. Bosch TM, Kjellberg LM, Bouwers A, Koeleman BP, Schellens JH, et al. 2005. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. Am. J. Pharmacogenomics 5:123-31
179. Gupta A, Zhang Y, Unadkat JD, Mao Q. 2004. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ ABLG2). J. Pharmacol. Exp. Ther. 310:334-41